{"filings":[{"id":788276,"accession_number":"0001493152-26-026780","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-06-02T12:48:18+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions starts multi-site FDA 510(k) study for opiate codeine fingerprint test","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Study will enroll 135 donor participants across multiple sites; partnered with CenExel Clinical Research.","Designed to validate accuracy, sensitivity, specificity of the Intelligent Fingerprinting Drug Screening System for workplace use.","Company expects to complete enrollment and data collection by end of July 2026.","User performance evaluation by non-laboratory personnel is a key part of the 510(k) submission.","Results will be confirmed via LC-MS/MS; study follows ICH GCP guidelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77004,"accession_number":"0001493152-26-022823","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-05-14T01:08:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Q3 revenue $1.06M (+46% YoY); cartridge sales up 59%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 cartridge revenue $703,538, up 59% YoY, representing 66% of total sales.","Gross profit margin expanded to 50.5% in Q3 (vs 46.8% prior year); nine-month margin 49.3%.","Nine-month revenue reached $3.07M, up 39% YoY; cash balance $6.86M at March 31, 2026.","Marketing spend in Q3 down 42% YoY while commercial momentum accelerated.","FDA 510(k) program advancing; new manufacturing partnership and Bouygues UK customer added."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":3069373.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95020,"accession_number":"0001493152-26-018002","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions reports 2,176,848 shares outstanding as of April 20, 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["As of April 20, 2026, total outstanding shares of INBS common stock were 2,176,848.","Increase resulted from exercise of previously issued warrants and sales under the At Market Offering Agreement with Ladenburg Thalmann.","Update reflects changes since the prior 8-K filed March 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107795,"accession_number":"0001493152-26-012173","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Intelligent Bio grants restricted shares to CEO/CFO/directors; updates ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Harry Simeonidis and CFO Spiro Sakiris each receive 9,150 time-vesting and 21,350 performance-vesting restricted shares.","Directors awarded 20,000 time-vesting shares; non-executive employees get 10,500 time-vesting and 24,500 performance-vesting shares.","Total outstanding shares as of March 23, 2026: 2,001,173, reflecting grants and warrant exercises.","Up to $3,966,316 in shares available for sale under existing ATM agreement with Ladenburg Thalmann; new prospectus supplement filed.","Performance-vesting shares tied to clinical trial, FDA submission, and commercial milestones; vest over up to 10 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107794,"accession_number":"0001493152-26-007973","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS ships first readers from new partner Syrma Johari; expects 40%+ cost savings, 20ppt gross margin boost","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First Intelligent Fingerprinting Drug Screening Readers manufactured by Syrma Johari MedTech deployed to U.K. and Europe customers.","Partnership expected to deliver annual production cost savings over 40%, improving gross margin by ~20 percentage points annually.","In-house lateral flow test strip production capacity doubled, enabling faster R&D and expanded drug panels.","Company confirms planned U.S. market entry (beyond Forensic Use Only) later in 2026, supported by scaled manufacturing capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107793,"accession_number":"0001493152-26-006317","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions Q2 revenue $896,774, up 48% YoY; reader sales surge 104%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $896,774, up 48% YoY; reader sales $246,519 (+104%), cartridge sales $516,754 (+33%).","First-half FY2026 revenue $2.01M (+36% YoY); gross margin improved to 49% from 39%.","Closed $10M private placement (net $9.4M received Jan 2, 2026) for working capital and FDA 510(k) submission.","Initiated additional clinical studies for FDA 510(k); plans for U.S. market entry.","Strategic alliance with Vlepis Pty Ltd for consumer health monitoring; major industrial service contract."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":2008571.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107792,"accession_number":"0001493152-26-005210","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio sees 48% Q2 revenue growth YoY, H1 revenue tops $2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fiscal Q2 2026 revenue expected up ~48% YoY; readers more than double (+104% YoY).","H1 2026 total revenue ~$2.01M (+36% YoY); cartridge sales +38%, readers +50%.","CEO cites expanding installed base as foundation for recurring cartridge revenue.","Company expects to file 10-Q for Q2 ended Dec 31, 2025 during week of Feb 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":2008571.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107791,"accession_number":"0001493152-26-004068","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions starts clinical studies for FDA 510(k) submission to detect codeine via fingerprint","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Partnered with Cliantha Research for a study in 40 adults to establish codeine detection cut-off levels.","Study uses Intelligent Fingerprinting Drug Screening System with DSR-Plus reader; full data analysis expected by end of March 2026.","Data will support FDA 510(k) submission and planned commercial launch into the multi-billion-dollar U.S. drug screening market.","Company notes over 500,000 tests already sold outside the U.S.; targeting workplace, clinical, and law enforcement segments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107790,"accession_number":"0001493152-26-000984","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Intelligent Bio Solutions regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 7, 2026 confirming compliance with Bid Price Rule.","Stock closed at or above $1.00 for 14 consecutive business days through Jan 6, 2026.","Deficiency notice from Dec 16, 2025 cited bid price below $1.00 for 30 days.","Compliance achieved; matter closed by Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107789,"accession_number":"0001493152-26-000176","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions closes $10M private placement; funds FDA submission and expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10M from sale of 2,298,850 units at $4.35/unit (common/pre-funded warrant + two Series K warrants).","At closing, 105,000 shares and 2,193,850 pre-funded warrants issued; post-closing shares outstanding ~1.2M (excluding warrants).","Series K warrants exercisable at $4.10/share for 5 years after registration statement declared effective by SEC.","CEO: proceeds to fund FDA 510(k) submission for fingerprint drug screening system and international market expansion.","Closing on Jan 2, 2026; resale registration statement to be filed by Jan 10, effective by Feb 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124191,"accession_number":"0001493152-25-029812","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions partners with Syrma Johari Medtech for manufacturing; expects ~20ppt gross margin improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership with Syrma Johari Medtech to scale production of fingerprint drug screening reader; expects annual production cost savings >40%.","Company anticipates ~20 percentage point improvement in gross margin compared to previous arrangement.","Syrma Johari's manufacturing capacity ~4x current; supports planned U.S. market entry in 2026.","Syrma Johari operates 14 manufacturing locations, certified to ISO 13485, MDSAP, FDA, TUV SUD, GMP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124190,"accession_number":"0001493152-25-028003","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq deficiency letter for bid price non-compliance; 1-for-10 reverse stock split effected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Dec 15 for closing bid price below $1 for 30 consecutive business days.","Initial compliance period runs through June 15, 2026; cure if bid price ≥ $1 for 10 consecutive days.","Filed and effected a 1-for-10 reverse stock split on Dec 15; split-adjusted trading began Dec 16.","If non-compliant by June 15, may qualify for an additional 180-day period if meeting other listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124189,"accession_number":"0001493152-25-027534","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions announces 1-for-10 reverse stock split effective Dec 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved by stockholders Oct 16, 2025; ratio set by Board at 1-for-10.","Shares outstanding to reduce from ~9.6M to ~0.96M; authorized shares unchanged at 100M.","No fractional shares; cash in lieu paid based on 5-day VWAP preceding split date.","Trading symbol INBS unchanged; new CUSIP 36151G709; split-adjusted trading starts Dec 16.","Historical net loss per share retroactively adjusted: FY2025 basic EPS becomes $(20.04) from $(2.00)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124188,"accession_number":"0001493152-25-025665","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions furnishes investor presentation for Dec 2, 2025; content not disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made a presentation available on its website under Investors section.","Presentation relates to business and operations, but specific details not provided in filing.","Filing is under Regulation FD; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124187,"accession_number":"0001493152-25-025410","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Intelligent Bio Solutions issues 75,000 restricted shares to MDM for advisory services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved issuance of 75,000 restricted shares of common stock (par value $0.01) to MDM Worldwide Solutions, Inc.","Shares issued as compensation for strategic communication advisory services under engagement letter effective Sept 11, 2025.","No cash proceeds received; shares issued in reliance on Section 4(a)(2) exemption from registration.","Issuance date of board approval: November 25, 2025; filing date: November 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124186,"accession_number":"0001493152-25-022005","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions reports record Q1 revenue of $1.11M, up 28% YoY; gross margin expands to 46.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.11M (+28% YoY, +32% sequential); cartridge sales 57.6% of total revenue.","Gross margin 46.6%, up 690 bps YoY, citing operational efficiency and product mix.","Added 33 new customer accounts; total active accounts 492 across 24+ countries.","Secured major contract with London public transport operator covering 14 sites and 4,400+ staff.","Expanded portfolio with SmarTest® Patch and global distribution deal with SMARTOX®."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1111797.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124185,"accession_number":"0001493152-25-021323","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions reports preliminary Q1 FY2026 revenue over $1M, up ~32% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary revenue >$1M for fiscal Q1 ended Sep 30, 2025; third consecutive quarter of growth.","Revenue up ~32% sequentially and ~28% year-over-year.","Cartridge revenue up ~43% YoY; reader revenue up ~23% YoY.","Growth driven by new customer accounts and strong sales of both cartridges and readers.","Full Q1 financial results expected in 10-Q filing week of Nov 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1111797.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124184,"accession_number":"0001493152-25-020262","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS adds 33 new customer accounts in Q1 FY2026, up 50% YoY; total active accounts exceed 480","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added 33 new customer accounts in fiscal Q1 ended Sept 30, 2025, a 50% increase YoY.","Total active accounts reached over 480; growth driven by maritime, transport, logistics, and new government sector.","91% of new accounts were first-time adopters; 9% expanded use within existing organizations.","Strong UK growth supported by distributor expansion across Europe and Middle East.","Global drug screening market projected at $17.1B by 2029, 15% CAGR, supporting INBS's expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124183,"accession_number":"0001493152-25-018806","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Intelligent Bio Solutions stockholders approve reverse stock split, warrant share issuance, and incentive plan expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected four directors: Boyages, Hurd, Isenberg, Fraser. Boyages received 1,349,921 for, 503,182 withheld.","Approved amendment to 2019 Long Term Incentive Plan, increasing authorized shares from 1.3M to 1.795M (495,000 new shares).","Approved issuance of up to 4,147,616 shares upon warrant exercise (over 20% of outstanding common stock).","Approved reverse stock split at ratio of 1-for-2 to 1-for-10 within 12 months, at Board's discretion, to regain Nasdaq bid price compliance.","Ratified UHY LLP as independent auditor for fiscal year ending June 30, 2026 (4,246,183 for, 227,964 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140855,"accession_number":"0001493152-25-015068","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions updates FDA 510(k) timeline; clearance expected H2 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Will commence clinical studies before year-end to gather additional data for FDA 510(k) resubmission for codeine fingerprint test.","Anticipates FDA 510(k) clearance for opiate codeine use in the second half of 2026.","Drug screening system adopted by over 450 accounts in 24 countries with 18 distribution partners.","Currently marketed outside U.S. and for forensic use only; FDA clearance would open broader U.S. commercial entry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140854,"accession_number":"0001493152-25-014961","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions extends Series H-1 warrant expiration to March 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved extension of Series H-1 Warrant termination date from Sept 27, 2025 to March 27, 2026.","Warrants cover 1,034,213 shares of common stock held by six warrant holders who consented.","Exercise prices and all other warrant terms remain unchanged; no consideration received for extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140853,"accession_number":"0001493152-25-013836","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions must resubmit FDA 510(k) for drug screening system after new info request","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requested new additional information in a letter dated September 12, 2025, requiring a new 510(k) resubmission.","Company previously responded to a February 2025 AI request covering over 70 items and submitted additional data in August 2025.","First-of-its-kind sweat-based device; FDA feedback described as not uncommon for breakthrough technologies.","Company expects an investor update within ten days outlining a revised timeline for FDA clearance.","International commercial activities continue to grow outside the U.S. while pursuing clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140852,"accession_number":"0001493152-25-012101","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions Q4 revenue up 16% YoY to $844K; progress on FDA 510(k) for U.S. market","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 FY2025 revenue $843,884 (+16% YoY); cartridge sales up 24% YoY.","Added 115 new accounts in FY2025; active base >450 across 24 countries with 18 distributors.","FDA 510(k) submission in progress for opiate test system; seeking U.S. clearance beyond Forensic Use Only.","Operational improvements: multilingual system, HubSpot CRM, new U.S. patent; accounting system upgrade underway.","Net loss or EPS not disclosed; company reports 'reduced net loss' but no specific figures."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3052532.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140851,"accession_number":"0001493152-25-011706","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions preliminary Q4 revenue up ~16% sequentially and YoY, driven by cartridge sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 FY2025 revenue growth of ~16% sequentially and year-over-year, driven by higher-margin cartridge sales and account growth.","Submitted FDA 510(k) application for opiate test system (codeine) to support planned U.S. market entry.","Completed multilingual system upgrades and launched localized websites to strengthen global adoption across Europe, Middle East, and Latin America.","Full-year FY2025 results and Form 10-K expected to be filed during the week of August 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3052532.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140850,"accession_number":"0001493152-25-011634","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"INBS submits FDA 510(k) AI response; expects clearance decision within six weeks","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted over 1,900 pages including 23 detailed test reports and 7,800 data lines from 10,000 hours of testing.","New cybersecurity and performance data reinforce fingerprint sweat drug screening platform for U.S. market entry in 2025.","Company serves 450+ accounts in 24 countries with 18 global distribution partners.","FDA response anticipated within six weeks.","CEO calls U.S. market entry a top priority given multi-billion-dollar commercial opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140849,"accession_number":"0001641172-25-021200","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions raises $3.8M via warrant exercise inducement, funds FDA 510k filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.8M from exercise of existing Series G and H-1 warrants at $1.90/share; closing July 28, 2025.","Holders get new Series J warrants for up to 4,046,456 shares at $1.90, exercisable upon stockholder approval, expiring 5.5 years from issuance.","Net proceeds to fund completion of 510k filing with FDA for Fingerprint Drug Screening System and general working capital.","Company issued 1,545,494 common shares via warrant exercise and amended H-1 warrants for 477,734 shares at $0.01/share.","Outstanding shares as of July 24, 2025: 7,433,658, including recent ATM and restricted stock issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140848,"accession_number":"0001641172-25-020729","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS strengthens FDA 510(k) with new fingerprint sweat detection data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cybersecurity penetration and EMC testing completed to validate platform resilience.","Ultra-Micro Balance scale confirmed ability to detect sweat volumes down to 0.0000001g.","Over 6,000 hours invested in testing, data aggregation, and analysis for submission.","Plan to submit findings to FDA in August, targeting U.S. market entry in 2025.","Company supports 450+ accounts across 24 countries with 18 distribution partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140847,"accession_number":"0001493152-25-011264","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions signs global distribution deal with Smartox for SmarTest Patch outside U.S. and Canada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership with Smartox LLC to distribute SmarTest Patch in international markets excluding U.S. and Canada.","SmarTest Patch provides continuous sweat-based drug detection for justice, rehabilitation, and workplace sectors.","INBS currently serves over 450 active accounts in 24 countries; deal adds complementary technology.","FDA clearance remains a strategic priority for U.S. expansion beyond forensic use only.","Global drug testing market projected to reach ~$18.6B by 2030 (Grand View Research)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140846,"accession_number":"0001641172-25-019745","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions adds SmarTest Patch wearable for extended drug detection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SmarTest Patch is a wearable device that continuously detects drugs via sweat over 7–10 days.","Developed by Smartox LLC; complements INBS's existing fingerprint sweat drug test.","Targets longer detection windows for justice, rehabilitation, and non-U.S. markets.","Detects cocaine, opiates, methamphetamines, marijuana, fentanyl, among others.","Expands product offering to address both short- and long-term testing needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140845,"accession_number":"0001641172-25-017814","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions amends CEO & CFO employment agreements, raises salaries","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO salary increased from AUD 560,000 to AUD 580,000; CFO from AUD 410,000 to AUD 430,000, effective June 30, 2025.","Enhanced severance: on termination without cause, 100% bonus and full equity vesting; after Change in Control adds 2x salary.","Non-compete revised to tiered restricted period (24 to 1 month) and broadened scope to prohibit any interest in competing entities.","Change in Control defined as acquisition of >20% voting stock, certain mergers, asset sale, or Board composition change, excluding stock repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158596,"accession_number":"0001641172-25-011176","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS surpasses 450 accounts; expands fingerprint drug testing into luxury marine, retail, and waste sectors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 450 active accounts globally, with 35 new accounts added in fiscal Q3.","Expanded into luxury marine sector in Europe, retail (major e-commerce) and waste/recycling in Australia.","Distributor network now includes 18 partners across 19 countries for localized support.","Plans to introduce a collected testing service to provide flexibility for high-volume customers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158595,"accession_number":"0001641172-25-010006","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","5.02","5.07","9.01"],"status":"ready","headline":"Intelligent Bio Solutions Q3 revenue $0.73M, up 20% QoQ; gross profit up 91% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.73M in fiscal Q3, up 20% sequentially; nine-month revenue $2.21M, down 7% YoY.","Gross profit $341,368, up 91% YoY; cartridge sales now 58% of total revenue for nine months.","Net loss attributable to company $2.54M, down from $2.98M YoY; cash $2.81M.","Added 35 new accounts in Q3, active customers exceed 450; launched multilingual system upgrades."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2641687.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176999,"accession_number":"0001641172-25-000789","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions granted 6th U.S. patent for drug screening cartridge; plans 2025 U.S. market entry","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted U.S. Patent No. 12259385 covering lateral flow test strip in fingerprint drug screening cartridge.","This is the company's sixth active U.S. patent, strengthening IP protection for its drug screening technology.","CEO states patent validates innovative tech; company plans U.S. market entry in 2025 following Dec 2024 FDA 510(k) submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176998,"accession_number":"0001641172-25-000626","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions' FDA clearance process on track for 2025 U.S. launch","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["510(k) submitted Dec 18, 2024; FDA issued Additional Information request, pausing 90-day review clock.","Company responding to AI request; clearance expected within 3–6 months or longer if additional data needed.","System demonstrated 94.1% accuracy in method comparison study; PK data closely aligned to blood at 95% confidence level.","Targeting opiate test system for codeine; full panel already in 19 countries with over 400 accounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176997,"accession_number":"0001641172-25-000172","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions expects sixth U.S. patent for fingerprint drug testing technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expected patent will protect lateral flow technology core to its drug screening system.","Patent strengthens IP portfolio as company plans U.S. market entry in 2025.","CEO Harry Simeonidis states protection is critical for scaling U.S. footprint.","Recent FDA 510(k) submission supports non-invasive sweat-based testing approach.","INBS provides non-invasive alternative to traditional drug screening methods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176996,"accession_number":"0001493152-25-010372","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Intelligent Bio Solutions sets 2024 annual meeting for May 8, 2025; proposal deadline March 24","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Annual Meeting to be held virtually on or about May 8, 2025.","Record date for voting set as March 18, 2025.","Stockholder proposals and director nominations must be received by March 24, 2025.","Deadline applies to both Rule 14a-8 proposals and other business under bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176995,"accession_number":"0001493152-25-009950","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions updates ATM offering capacity: $1.38M shares remain available","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["As of March 11, 2025, the Company had 6,783,543 shares of common stock outstanding.","Up to $1,376,530 in additional shares remain available for sale under the existing ATM Agreement with Ladenburg Thalmann.","A prospectus supplement was filed on March 11, 2025, to allow continued offer and sale of these additional shares.","The ATM facility was originally established on September 18, 2024, for up to $3.0 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176994,"accession_number":"0001493152-25-007928","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions raises $3.0M in underwritten public offering; over-allotment fully exercised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $3.0M from 1.5M shares at $2.00 per share including full over-allotment exercise.","Ladenburg Thalmann sole bookrunner; underwriting discount of 8% plus 1% management fee.","Proceeds to be used for working capital and general corporate purposes.","Representative warrants issued for 75,000 shares at $2.50 expiring February 2030.","Post-offering shares outstanding: 6,778,837."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176993,"accession_number":"0001493152-25-006478","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INBS Q2 FY2025 revenue falls 20% YoY; net loss widens to $2.26M; gross margin up 11pts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $607,494, down 20% YoY; net loss $2.25M vs $1.97M.","Gross margin for six months improved to 38.5% from 27.7% on higher cartridge sales.","FDA 510(k) submitted in Dec 2024; planning US market entry in 2025.","Cash $2.24M; equity $4.20M as of Dec 31, 2024.","Added 19 accounts; total 400+ active accounts in 19 countries."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1739549.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176992,"accession_number":"0001493152-25-005677","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INBS reports prelim Q2 revenue ~$0.61M; gross margin up to 38.5%; FDA 510(k) submitted for U.S. market entry in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q2 FY2025 revenue ~$0.61M; 6-month revenue ~$1.48M; gross profit margin improved to 38.5% from 27.7%.","Fiscal year 2024 revenues grew 148% YoY; over 400 accounts in 19 countries with customer employee base ~1.4M.","Submitted 510(k) pre-market notification to FDA in Dec 2024; on track for U.S. market entry in 2025.","PK study showed fingerprint sweat correlates with blood at 95% confidence; Method Comparison Study showed ~94% accuracy.","Gross profit up 32.6% to $0.57M for six months; strategic focus on higher-margin cartridge sales driving margin expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176991,"accession_number":"0001493152-25-005469","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avon Freight Group selects INBS fingerprint drug testing for 3 UK sites","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Avon Freight Group selects INBS fingerprint drug testing for random testing across three UK sites.","INBS now serves over 400 accounts in 19 countries; targeting U.S. expansion after FDA 510(k) submission in Dec 2024.","UK drug testing market projected to reach $453M by 2030, positioning INBS for growth.","Avon previously used external oral swab tests; switch aims for less invasive, cost-effective solution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176990,"accession_number":"0001493152-25-005244","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INBS preliminary Q2 revenue $0.61M; six-month gross profit up 32.6% to $0.57M, margin 38.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Unaudited revenue $0.61M for Q2, $1.48M for six months ended Dec 31, 2024.","Gross profit for six months increased 32.6% to $0.57M; gross margin expanded to 38.5% from 27.7%.","Higher-margin cartridge sales driving profitability; 400+ active accounts.","FDA 510(k) submitted for fingerprint drug screening system to enter U.S. market in 2025.","Calendar 2024 revenue grew 23% year-on-year; expects to file 10-Q in week of Feb 10."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1739549.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176989,"accession_number":"0001493152-25-004490","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions plans multilingual upgrade for drug screening system, aims to reach 4B users","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Multilingual upgrade will support languages across Americas, Europe, Asia Pacific, and Middle East, accessible to over 4 billion speakers worldwide.","Supports planned 2025 entry into US market following FDA 510(k) submission in December 2024.","Company has existing presence in 19 countries; targets safety-critical industries like construction, mining, and transport.","Drug screening market projected to reach approximately $8 billion globally by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176988,"accession_number":"0001493152-25-004180","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions adds Quantum TM, expanding fingerprint drug testing to 10 UK sites","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quantum Traffic Management adopts INBS fingerprint drug screening across 10 UK sites, replacing saliva/urine methods.","INBS now serves over 400 accounts across 19 countries; plans US market entry in 2025.","INBS filed FDA 510(k) submission in December 2024 for US clearance.","Quantum TM's managing director highlights improved efficiency with in-house rapid testing.","Serves industries including construction, manufacturing, transport, and logistics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176987,"accession_number":"0001493152-25-004025","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions partners with IVY Diagnostics to expand EU & Middle East drug screening market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership with IVY Diagnostics Srl as key distributor for fingerprint drug screening in Europe and Middle East.","IVY Diagnostics secured a tender for drug rehab programs across Italy using INBS' fingerprint drug screening technology.","INBS' drug screening system undergoing trial with Turin police for roadside screening to test fingerprint-based method.","Expansion to multiple countries: Romania, Hungary, Slovakia, Austria, Scandinavia, UAE, Saudi Arabia, Qatar.","European drug screening market projected at $3.6B by 2030; Middle East & Africa at $432.7M (Grand View Research)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176986,"accession_number":"0001493152-25-001055","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Intelligent Bio Solutions reports 4,807,068 shares outstanding as of Jan 2, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Share count follows sales under ATM agreement with Ladenburg Thalmann & Co. Inc.","Includes issuance of 8,109 restricted shares under ClearThink Capital Partners advisory agreement.","No other material events disclosed; update is procedural following equity issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193779,"accession_number":"0001493152-24-050646","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS files 510(k) with FDA for fingerprint sweat drug test; 94.1% accuracy, 2025 US launch target","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["510(k) submission for Intelligent Fingerprinting Drug Screening System; method comparison study showed 94.1% accuracy.","PK study demonstrated fingerprint sweat drug detection closely aligned to blood at 95% confidence level.","System provides non-invasive results within 10 minutes; already adopted in international markets.","US market entry planned for 2025; targets safety-critical industries (construction, mining, transportation).","Potential applications in law enforcement, drug rehabilitation, and forensic sectors for diverse revenue streams."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193778,"accession_number":"0001493152-24-048518","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions furnishes corporate presentation; no specific financial disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation made available on Dec 3, 2024 via investor section of company website.","No financial results, guidance, or material operational updates provided in the filing.","Exhibit includes only a presentation cover; substantive content not disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193777,"accession_number":"0001493152-24-047842","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS fingerprint drug test achieves 94.1% accuracy; FDA submission on track for Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Method comparison study with 135 donors and 9 operators shows 94.1% accuracy, 82.2% sensitivity, 100% specificity for opiate detection.","FDA 510(k) submission expected in Q4 2024; includes data from PK study and method study.","System components evaluated: Drug Screening Cartridge, Reader, and Fingerprint Collection Kit.","CEO Harry Simeonidis states results reaffirm accuracy and reliability for workplace drug testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193776,"accession_number":"0001493152-24-047009","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Intelligent Bio Solutions releases PK study video for FDA 510(k) and raises $250,802 via ATM","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Released video detailing initial results from PK study required for FDA 510(k) submission; no specific data provided.","Raised net proceeds of $250,802 through ATM offering, selling 154,282 shares combined (Sep-Nov 2024).","Net proceeds include $34,511 from 17,167 shares sold Sep 18-30 and $216,291 from 137,115 shares sold Oct 1-Nov 19."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-11-20T23:59:59+00:00|193776"}